The aim of this study is to investigate the role of transmission of vagal cholinerg for the GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin response by using atropin administration. The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with an intact nervous supply with and without atropin administration.
GLP-1 is a importent enterogastron and incretin hormone. Rapid degradation of GLP-1 by dipeptidyl peptidase 4 (DPP-4) suggests that GLP-1 may act locally (through vagal afferents) before being degraded. We aimed to clarify the role of vagal innervation on the incretin effect.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
10
Diabetes research Division, Department of Internal Medicin, Gentofte Hospital
Hellerup, Denmark
RECRUITINGDiabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen Denmark
Hellerup, Denmark
RECRUITINGinsulin secretion
The insulin secretion during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration is evaluated. Also the insulin secretion during lightly elevated blood glucose during a sham-feeding with and without atropin administration is evaluated.
Time frame: tree hours
Plasma PP
20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration.
Time frame: 20 time points within tree hours
Plasma glucose
30 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration.
Time frame: 30 within tree hours
Plasma GLP-1
20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration.
Time frame: 20 time points within tree hours
Plasma GLP-1
18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration.
Time frame: 18 time points within tree hours
Plasma GLP-2
18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration.
Time frame: 18 time points within tree hours
Plasma GIP
18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration.
Time frame: 18 timepoints within tree hours
Plasma glucagon
18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration.
Time frame: 18 timepoints within tree hours
Plasma glucose
33 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration.
Time frame: 33 timepoints within tree hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.